Literature DB >> 8500226

Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes.

E Smeland1, R M Bremnes, A Bessesen, R Jaeger, J Aarbakke.   

Abstract

The accumulation of methotrexate (MTX) in the presence of vinblastine (VBL) and vincristine (VCR) was studied in isolated rat hepatocytes. In accordance with our recent study on vindesine (VDS), we found VBL and VCR to reduce net MTX accumulation significantly at 15 min after MTX addition. Drug concentrations of 100 microM VBL and 500 microM VCR led to 67% and 82% reductions in intracellular MTX, respectively. Since there was only a slight inhibition of MTX efflux by 100 microM VBL, the accumulation data demonstrate that the major effect of VBL is on MTX influx. Dixon-plot analyses are suggestive of competitive inhibition of the MTX influx, yielding inhibition constants (Ki values) of 55 microM for VBL and 110 microM for VCR. Since the Ki values correspond grossly to plasma levels obtained in humans shortly after the infusion of therapeutic doses of the vinca alkaloids studied herein, the interaction with MTX uptake could serve to diminish the toxicity of MTX to nonmalignant cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500226     DOI: 10.1007/BF00685837

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  57 in total

1.  Pharmacokinetics of vindesine and vincristine in humans.

Authors:  R J Owellen; M A Root; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

2.  The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells.

Authors:  R D Warren; A P Nichols; R A Bender
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

3.  Induction of methotrexate release from rat hepatocytes in suspension by alpha-adrenergic agents: involvement of calcium and metabolic energy.

Authors:  D A Gewirtz; J K Randolph; M Jaramillo
Journal:  Arch Biochem Biophys       Date:  1985-02-15       Impact factor: 4.013

4.  Membrane tubulin.

Authors:  C S Regula; P R Sager; R D Berlin
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

5.  The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia.

Authors:  R F Zager; S A Frisby; V T Oliverio
Journal:  Cancer Res       Date:  1973-07       Impact factor: 12.701

6.  Serum protein reduction of the enhancement of methotrexate accumulation by vincristine and 4'-demethylepipodophyllotoxin in the Ehrlich ascites tumor cell in vitro.

Authors:  D A Gewirtz
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

7.  Transport of methotrexate in basolateral membrane vesicles from rat liver.

Authors:  D W Horne; K A Reed
Journal:  Arch Biochem Biophys       Date:  1992-10       Impact factor: 4.013

8.  Optimum scheduling during combination chemotherapy of murine leukemia. Additional examples of schedule-dependent synergism between S-phase-specific antimetabolites and agents inducing mitotic or pre-mitotic (G2) arrest.

Authors:  F M Sirotnak; F A Schmid; C Temple; J A Montgomery
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Acute hepatotoxicity after high-dose methotrexate administration to rats.

Authors:  R M Bremnes; E Smeland; N E Huseby; T J Eide; J Aarbakke
Journal:  Pharmacol Toxicol       Date:  1991-08

10.  Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells.

Authors:  D W Fry; J C Yalowich; I D Goldman
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

View more
  3 in total

1.  Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine.

Authors:  Johan Nicolaï; Louise Thevelin; Qi Bing; Bruno Stieger; Hugues Chanteux; Patrick Augustijns; Pieter Annaert
Journal:  Pharm Res       Date:  2017-08-21       Impact factor: 4.200

2.  Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

Authors:  M Joerger; A D R Huitema; H J G D van den Bongard; P Baas; J H Schornagel; J H M Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

3.  Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.

Authors:  Chenrong Huang; Fan Xia; Ling Xue; Linsheng Liu; Yicong Bian; Zhengming Jin; Liyan Miao
Journal:  Cancer Chemother Pharmacol       Date:  2019-11-05       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.